CRB Inverbío

ANGEL SANTOS

Barcelona, 5 de marzo de 2014

INVESTING IN BIOMEDICINE AND LIFE SCIENCES IN SPAIN

EXECUTIVE SUMMARY

- CRB Inverbío is a Venture Capital GP focused on life sciences investing in innovative early stage start ups in biotech, med tech and related fields.
- CRB Inverbío manages two Funds:
 - CRB SCR, already fully invested
 - CRB Bio II FCR
- CRB SCR, has a diversified portfolio of six companies in the biomedicine sector at different stages
 of development providing therapeutic and diagnostic solutions for some of the current most significant
 diseases, such as cancer, Alzheimer, NASH, lactose intolerance, therapeutic siRNA applications and
 nanotechnology for therapeutical applications and drug delivery.
- CRB Bio II FCR is a new VC Fund that will invest in 12-14 innovative companies in life sciences with a target size of €60M. The first closing of €30M was held on June 2012.
- Investments up to date:
 - EUR 2.0 million in Oncovision, a company focused on Molecular Vision and Medical Imaging.
 - EUR 1.8 million in Amadix, a development company for cancer diagnostic tools.
 - EUR 1.8 million in Raman Health Technologies, company developing a new non invasive diagnostic technology platform based on Raman laser and Infrarred spectroscopy
 - EUR 2.0 million in Health in Code, a genetic diagnostic company specialized in cardiomyopathies
 - EUR 2.5 million final target investment in Iden Biotechnology, an agri-biotech R&D company



SENIOR TEAM WITH BROAD CROSS-FUNCTIONAL EXPERIENCE

EXECUTIVE PARTNERS

Enrique Castellón - President.

MD Internal Medicine, BA Economics, MPH MSc Health Policy Harvard University, Former Chairman and Founder of the Spanish Drug Agency, National Institute for Cancer Research (CNIO) and National Institute for Cardiovascular Diseases (CNIC), deputy Minister for Health and Social Services in the region of Madrid, former General Director of the Galician Health Services



Pablo Cabello - Technical and Scientific Director Molecular Biologist. Professional experience in the Instituto de Biología Celular. Histopathology services in the Fundación Jiménez Diaz Hospital.

20 years in the Molecular Genetics laboratory of the Hospital Ramón y Cajal



Angel Santos - Director of Business Development Engineer. Has developed his career in Spain, the UK and the US in Johnson's Wax and Lilly, in which he has held different leadership positions in general management, strategic and corporate development, M&A, business development and innovation management.



Manuel Castellón – Managing Director

Lawyer and Economist. Master in Legal Counselling. 25 years of experience as corporate lawyer. Director and certified company counsel in various media companies. Founder of Castellón Abogados.



NON EXECUTIVE PARTNERS

César Molinas - Mathematician and Doctor of Economic Sciences (UB). He is a founding partner of the Multa Paucis consultancy and consultant for Providentia Capital. Formerly Managing Director Merrill Lynch (London), Director of Planning at the Ministry of Economy, Head of Analysis at the CNMV. Has served as independent Director in many corporations including Renfe and Correos.



Luis Escauriaza - Economist. Former head of cabinet of the Economy Ministry and General Director for SMEs in the Ministry of Industry and Energy. President of the Banco de Crédito Industrial and Banco de Negocios Argentaria. CEO of the Banco de Crédito Local. Member of the Board of the Banco Hipotecario de España, Fuerzas Eléctricas de Cataluña (FECSA) and Banco Internacional de Andorra and others.



Juan María Aguirre - Economist from ICADE and Master in Financial Management. Founder of Quantica Investors. Director of BBVA Elcano Empresarial SRC, Maltisa SICAV and Quantop SICAV. Formerly Head of financial investments in Grupo Torreal, Financial Director of Mercedes Benz and Banco del Progreso.



INVESTMENT DIRECTOR

Emilio Ayanz - Bachelor of Business Administration degree and certified financial analyst. Management experience as an investment banker, Venture capital and financial management in the USA, UK and Spain. Prior to join CRB Inverbío he was financial director in Aries Ingeniería and in Minerva Capital.





TIMELINE

EARLY YEARS

2001 - 2007

DEVELOPMENT OF CRB EARLY STAGE INVESTMENT MODEL **2007 - 2011**


CONSOLIDATION OF CRB
INVERBÍO AND 2ND FUND
2011 – to date

- Exploratory
- Informal structure
- Angel and seed investments by founders and Fs
- Limited funding available

- Consolidation and expansion of management team
- Formal VC structure
- Constitution of CRB SCR
- Formal Fund raising to institutional and professional investors
- Raised 11M

- Constitution of CRB Inverbio VC
 Management Firm
- Launch of CRB Bio II
- Consolidation of track record and portfolio
- Positioned as reference investor in Spain's Life Sciences sector





CREATING A HIGH VALUE PORTFOLIO

VISION TECHNOLOGY FOR DIAGNOSTIC AND TREATMENT OF CANCER



 SENTINELLA The first integrated radiocontrolled surgical platform for detecting the extent and severity of several types of cancer in the operating room.

Developing 3D and real time imaging.



 ALBIRA Advanced in-vivo research system for small animals that incorporates the three key molecular view technologies: PET, SPECT, and CT.

Global distribution agreement with market leader Bruker International














CREATING A LEADER IN CANCER MOLECULAR DIAGNOSTICS







- One of the first merger by takeover in the Spanish biotech sector
- Strong portfolio of 5 programs at different development stage
- Solid international expert team and model of In-Licensing
- Strategic agreement with Hospital Vall d'Hebrón





NEW OPORTUNITIES ANALYZED

50


LASER RAMAN PLATFORM FOR NON INVASIVE DIAGNOSTICS







- May 2011: a CSIC study from Instituto de Estructura de la Materia established use of laser Raman technology in the detection of AD in a blood sample.
- Study demonstrated excellent precision in AD early stages
- The technology is based upon Raman capability of identifying compounds based on its spectrum.
- The Instituto de Astrobiología de Valladolid (CAB) develops a system based on laser Raman and IR to be sent to Mars in the ESA ExoMars 2018 mission to search for organic life traces
- · The company is based on coupling both technologies and IP





SPECIALISTS IN ADVANCED DIAGNOSTICS IN healthincode INHERITED CARDIOVASCULAR DISFASES

- Spin off from the Universidad of La Coruña.
- Genetic diagnostics in inherited cardiovascular diseases allows early detection and prevention of sudden death in athletes.
- Provides physicians the opportunity to carry out personalized medicine with the support of genetic diagnostic.
- CRB Bio II investment will go to optimize the analysis process with NGS, the development of personalized patient reports and to finance international expansion.

2007-2008 2009-2010 2011-2012

proporciona un listado de test genómicos y sus

aplicaciones en la práctica clínica según tres niveles de evidencia: Tier 1, 2 y 3. Tier 1: se recomienda su uso en clinica Tier 2: pueden ser útiles para toma de decisiones

CDC Office of Public Health Genomics

Current status: term sheet signed

Tests genéticos aprobados como Tests genéticos reconocidos por CDC¹ Circulation Publicaciones en PubMed dispositivo médico por la FDA como Tier 1 o Tier 2 50.000 12 40.000 20 29.913 30.000 20.000 10.000

1- Centers for Disease Control and Prevention uentes: www.pubmed.com; www.cdc.gov; www.fda.gov; Khoury et al Genet Med 2010:12(11):680-683; FDA Medical Devices, Lista de Human Genetic Test (clasificación Nucleic Acid

2005-2008

2001-2004

2009-2012

2000-2005

Búsqueda utilizando "genetic test"

2006-2011






5.1. Genetic Testing Strategies/Family Screening—Recommendations

- 1. Evaluation of familial inheritance and genetic coun seling is recommended as part of the assessment of
- patients with HCM. 17.31.93-96 (Level of Evidence: B)

 2. Patients who undergo genetic testing should also undergo counseling by someone knowledgeable in the genetics of cardiovascular disease so that results and their clinical significance can be appropriately re-viewed with the patient.⁹⁷⁻¹⁰¹ (Level of Evidence; B)
- 3. Screening (clinical, with or without genetic testing) is recommended in first-degree relatives of patients with HCM. 17,31,33,94,96,102,103 (Level of Evidence: B) 4. Genetic testing for HCM and other genetic causes of
- unexplained cardiac hypertrophy is recommended in patients with an atypical clinical presentation of HCM or when another genetic condition is suspected to be the cause. 104-106 (Level of Evidence: B)

1. Genetic testing is reasonable in the index patient to facilitate the identification of first-degree family members at risk for developing HCM.17,95,102 (Level of Evidence: B)





European Heart Journal Advance Access published September 7, 2010



CURRENT OPINION

Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases

Philippe Charron¹, Michael Arad², Eloisa Arbustini³, Cristina Basso⁴, Zofia Bilinska² Perry Elliott⁴, Tiina Helio⁷, Andre Keren⁸, William J. McKenna⁴, Lorenzo Sabine Pankuweit¹⁰, Andreas Perrot¹¹, Claudio Rapezzi¹², Arsen Ristic¹³, Hubert Seggewiss¹⁴, Irene van Langen¹⁵, and Luigi Tavazzi¹⁴⁰

KEY MESSAGE & Genetic testing and positive diagnosis (as a KEY MESSAGE 5: Genetic testing and predictive diagnosis complete analysis of potential genes of interest in the proband of a family)

- . Genetic testing is appropriate for the diagnosis of a rare or particular cardiomyopathy, especially in the presence of atypical phenotypic features, in the setting of expert teams after detailed (ii). Genetic testing is therefore indicated in the proband of a
- · Genetic testing is not indicated for the diagnosis of a borderline or doubtful cardiomyopathy, except selected cases in the setting of expert teams after detailed clinical and family assessment.
- (i) Genetic testing is appropriate for predictive diagnosis in asymptomatic relatives of a patient with a cardiomyopathy when the disease-causing mutation has been previously
- family (the first or most clearly affected patient with a cardtamily (the first or most clearly affected patient with a cardi-omyopathy) as a first condition for the proposal of prediction diagnosis within the family. NBI: Post-mortem (necropsy) molecular analyses can be considered in the proband if he she is the only patient with the cardiomyopathy within the family, NB2: This is appropriate, whatever may be the 'familial or 'sporadic' context, in HCM and ARVC, but questionable is
- or 'spondic' context, in HCM' and ARVC, but questionable in spondic DO'st and spondic RCM (except in the presence of stypical associated phenotype or red flags).

 (iii) Predictive diagnosis in children can be considered at the age at which cardiac examination is useful (10–12 years of age for most cardiomyopathies).

CONTRIBUTING TO THE SUSTAINABLE PRODUCTION OF FOOD












Genetic improvement

- Increase of productivity
- Increase of starch content
- Resistance to abiotic stress (cold, XX



Agro biologics

- Increase of productivity and agronomic characteristics of XX
- Resistance to biotic stress



INNVIERTE PROGRAM

INNVIERTE PROGRAM

SUMMARY

- The INNVIERTE program is a line of action framed in the State strategy of innovation (e2i), approved by the Council of Ministers and conducted by CDTI which aims to promote business innovation through support to venture capital investment in technology-based or innovative companies.
- INNVIERTE program seeks to promote the entrance of private capital into Spanish technological SMEs under market conditions, in order to not only support the technological activities of SMEs, but provide capacity management and internationalization and market knowledge.
- CRB Inverbío SGECR submitted its candidature through the CRB Bio II Fund on October 15, 2013.
- On December 4 2013, CDTI informed of the acceptance of CRB Inverbio´s proposal and the participation in CRB Bio II with the amount of €10M €14 M, subject to the contribution of an equal amount of private funds.



CRB Inverbío

ANGEL SANTOS

Barcelona, 5 de marzo de 2014